UK Pharmaceutical Market Report by Type (Pharmaceutical Drugs, Biologics), Routes of Administration (Oral, Topical, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospital and ASCs, Clinics, and Others), and Region 2024-2032

UK Pharmaceutical Market Report by Type (Pharmaceutical Drugs, Biologics), Routes of Administration (Oral, Topical, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospital and ASCs, Clinics, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112025A24813

UK Pharmaceutical Market Overview:

The UK pharmaceutical market size reached USD 38.82 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 73.19 Billion by 2032, exhibiting a growth rate (CAGR) of 6.70% during 2024-2032. The heightened prevalence of chronic diseases among the masses, rising advancements in personalized medicine and bioengineering, and implementation of favorable government policies are some of the factors supporting the growth of the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 USD 38.82 Billion
Market Forecast in 2032 USD 73.19 Billion
Market Growth Rate 2024-2032 6.70%


UK Pharmaceutical Market Trends:

Advancements in Biotechnology and Personalized Medicine

Bioengineering and personalized medical technologies are growing rapidly in the UK. These trends are improving efficiency in the healthcare industry by offering individualized treatment plans developed from personal genetic profiles. These advancements create precision medicine treatment options that improve efficacy and reduce negative side effects. In 2024, the NHS treated its first patient in England with a personalized vaccine targeting bowel cancer, as part of a clinical trial. Personalized medicine is revolutionizing how complex diseases, such as cancer and autoimmune disorders, are treated, aligning with trends emphasizing precision over a one-size-fits-all approach. The expansion of biotechnology companies and investments in research and development (R&D) is leading to an increase in biotech-related investments.

Aging Population and Chronic Disease Prevalence

The UK's aging population is a primary driver of pharmaceutical demand, particularly in areas related to chronic diseases, such as cardiovascular disorders, diabetes, and neurodegenerative conditions. As per the Office for National Statistics (ONS), over the next 15 years, the size of the UK population aged 85 years and above is expected to increase from 1.6 million to 2.6 million, leading to an increased demand for long-term medications and treatments. In response, pharmaceutical companies are launching several age-targeted drugs in recent years. Moreover, pharmaceutical companies are launching drugs for the treatment of hyperkalemia, which primarily affects older adults with kidney issues. The rise in conditions like Alzheimer's, Parkinson’s, and heart disease is influencing the development of innovative therapies. This demographic shift is catalyzing the demand on healthcare services and pharmaceutical companies to produce more targeted and effective treatments.

Government Policies and Healthcare Reforms

Government initiatives and healthcare reforms play a crucial role in bolstering the market growth in the UK. The UK government’s focus on accelerating drug approvals and enhancing access to medicines is creating a favorable environment for pharmaceutical companies. The government provided £200 million to the NHS in January 2023 to fund step-down capacity and £50 million in capital spending to expand the discharge lounges and ambulance hubs in hospitals. Additionally, the Department of Health and Social Care (DHSC) opened £400m investment program to fasten and enhance clinical trials in UK in 2024. This investment is considered to increase the UK’s capacity for clinical trials and provide researchers better access to the latest equipment and technology. As part of the program, up to 18 new ‘Commercial Research Delivery Centers’ will be opened across the UK, which will support patient recruitment into trials.

UK Pharmaceutical Market News:

  • May 2024: Marksans Pharma obtained UK healthcare regulator’s nod for marketing new oral solution, Levetiracetam Relonchem 100 mg/mL. It will be used to treat epilepsy and help control certain seizures.
  • August 2023: The state-run national health service in Britain will provide an injection that treats cancer of innumerable patients and cut treatment times by up to 3 quarters. The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the injection, and it will help in treating patients with immunotherapy and atezolizumab.

UK Pharmaceutical Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on type, routes of administration, distribution channel, and end user.

Type Insights:

  • Pharmaceutical Drugs
    • Cardiovascular Drugs
    • Dermatology Drugs
    • Gastrointestinal Drugs
    • Genito-Urinary Drugs
    • Hematology Drugs
    • Anti-Infective Drugs
    • Metabolic Disorder Drugs
    • Musculoskeletal Disorder Drugs
    • Central Nervous System Drugs
    • Oncology Drugs
    • Ophthalmology Drugs
    • Respiratory Diseases Drugs
  • Biologics         
    • Monoclonal Antibodies (MAbS)
    • Therapeutic Proteins
    • Vaccines
       

The report has provided a detailed breakup and analysis of the market based on the type. This includes pharmaceutical drugs (cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal disorder drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs) and biologics (monoclonal antibodies (MAbS), therapeutic proteins, and vaccines).

Routes of Administration Insights:

  • Oral
  • Topical
  • Parenteral
  • Others
     

A detailed breakup and analysis of the market based on the routes of administration have also been provided in the report. This includes oral, topical, parenteral, and others.

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
     

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, and online pharmacy.

End User Insights:

  • Hospitals and ASCs
  • Clinics
  • Others
     

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospital and ASCs, clinics, and others.

Regional Insights:

  • London
  • South East
  • North West
  • East of England
  • South West
  • Scotland
  • West Midlands
  • Yorkshire and The Humber
  • East Midlands
  • Others
     

The report has also provided a comprehensive analysis of all the major regional markets, which include London, South East, North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, and Others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

UK Pharmaceutical Market Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units USD Billion
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
  • Type
  • Routes of Administration
  • Distribution Channel
  • End User
  • Region 
Types Covered
  • Pharmaceutical Drugs: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs
  • Biologics: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
Routes of Administrations Covered Oral, Topical, Parenteral, Others
Distribution Channels Covered Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
End Users Covered Hospital and ASCs, Clinics, Others
Regions Covered London, South East, North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, Others.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the UK pharmaceutical market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the UK pharmaceutical market?
  • What is the breakup of the UK pharmaceutical market on the basis of type?
  • What is the breakup of the UK pharmaceutical market on the basis of routes of administration?
  • What is the breakup of the UK pharmaceutical market on the basis of distribution channel?
  • What is the breakup of the UK pharmaceutical market on the basis of end user?
  • What are the various stages in the value chain of the UK pharmaceutical market? 
  • What are the key driving factors and challenges in the UK pharmaceutical?
  • What is the structure of the UK pharmaceutical market and who are the key players?
  • What is the degree of competition in the UK pharmaceutical market? 

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the UK pharmaceutical market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the UK pharmaceutical market.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the UK pharmaceutical industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
UK Pharmaceutical Market Report by Type (Pharmaceutical Drugs, Biologics), Routes of Administration (Oral, Topical, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospital and ASCs, Clinics, and Others), and Region 2024-2032
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials